Bruker Corp Stock Price, News & Analysis

Bruker Corporation (Nasdaq: BRKR) has launched the FluoroType SARS-CoV-2 varID Q assay, a new mid-plex PCR panel capable of detecting multiple SARS-CoV-2 variants simultaneously. This CE-IVD marked assay boasts an impressive sensitivity of 98% and 100% specificity, effectively identifying key mutations of the virus. It quantifies viral load in standardized International Units, providing critical insights into patient infectiousness. The assay enhances laboratory efficiency, offering quicker results and lower operational costs compared to sequencing techniques.

Bruker Corporation (Nasdaq: BRKR) launched two new timsTOF instruments at its virtual 4D-Proteomics™ eXceed Symposium. The timsTOF trueSCP enhances quantitative single-cell proteomics, achieving 1,500 proteins per cell, while the timsTOF Pro 2 boasts advanced capabilities for unbiased 4D-Proteomics, identifying over 6,000 proteins and 60,000 unique peptides. New PaSER software supports real-time peptide sequencing and CCS-enabled bioinformatics, improving identification accuracy. CEO Frank H. Laukien emphasized the significance of these innovations for advancing cancer detection and personalized therapy.

A recent clinical research collaboration has explored transient and persistent systemic changes in COVID-19 patient blood samples, revealing biochemical abnormalities related to long COVID symptoms that can persist for months. Using an innovative assay platform of NMR spectroscopy and mass spectrometry, the study identified that over 57% of mildly affected COVID-19 patients experience ongoing health issues three months post-infection. The research emphasizes the need for longitudinal studies to understand future health risks better.

Bruker Corporation (Nasdaq: BRKR) announced a new share repurchase authorization for up to $500 million over two years, starting May 13, 2021. This initiative reflects the company's confidence in its long-term prospects. The repurchase may occur through various methods and can be suspended at any time. Additionally, Bruker declared a quarterly cash dividend of $0.04 per share, set for June 18, 2021, to stockholders of record as of June 1, 2021.

Bruker Corporation (Nasdaq: BRKR) has authorized a new share repurchase plan of up to $500 million over two years starting May 13, 2021. This decision reflects the company's confidence in its long-term prospects. Shares may be repurchased via open market transactions or trading plans under Rule 10b5-1. Additionally, Bruker declared a quarterly cash dividend of $0.04 per share, payable on June 18, 2021, to stockholders of record as of June 1, 2021.

Bruker Corporation has announced that its 1H-NMR spectroscopy has been officially incorporated by the International Organization of Vine and Wine (OIV) for quantifying key wine parameters such as glucose and acidity. This advancement allows for simultaneous and accurate measurement of 53 compounds in a single automated process, addressing the demand for authenticity in wine supply chains. Bruker's NMR Wine-Profiling™ 4.0 enhances supply chain verification and counters fraud, marking a significant innovation in the wine industry.

Bruker Corporation (Nasdaq: BRKR) announced its participation in three upcoming virtual healthcare conferences. The events include the BofA Securities 2021 Health Care Conference on May 11, 2021, the UBS Global Healthcare Virtual Conference on May 24, 2021, and the Jefferies Virtual Healthcare Conference on June 2, 2021. Key executives, including Frank Laukien and Mark Munch, will present. Live webcasts and replays will be accessible on the Investor Relations section of Bruker's website for 30 days post-event.

Bruker Corporation (Nasdaq: BRKR) reported first-quarter revenues of $554.7 million, up 30.8% year-over-year from $424.0 million. Organic growth was 23.8%, with foreign currency effects contributing 6.2%. Bruker Scientific Instruments saw revenues rise 32.7% to $506.2 million, while Bruker Energy & Supercon Technologies increased 13.4% to $52.4 million. GAAP operating income surged to $89.1 million with a margin of 16.1%, and EPS reached $0.37. The company raised its FY 2021 guidance, expecting 14%-16% revenue growth and non-GAAP EPS of $1.82 to $1.87.

Bruker Corporation (Nasdaq: BRKR) reported preliminary revenue for Q1 2021 between $549 million and $554 million, reflecting 30% to 31% growth year-over-year. Excluding effects from currency fluctuations and acquisitions, the non-GAAP organic revenue growth is estimated at 22% to 23%, exceeding earlier forecasts of 15%. Revenue growth was attributed to strong performance in all three Bruker Scientific Instrument groups, including notable sales of GHz-class NMR systems. Full financial results are expected on May 5, 2021.